FDA Wants Solzira Restless Legs Data Reformatted
This article was originally published in The Pink Sheet Daily
Executive Summary
Filing’s content is unaffected, says GlaxoSmithKline, which withdrew the recently submitted NDA but will resubmit it “as quickly as possible.”
You may also be interested in...
XenoPort’s Second Pain Failure Puts Heat On Restless Legs
With generic Requips making headway in restless legs, investors had counted on cashing in on diabetic neuropathy.
XenoPort’s Second Pain Failure Puts Heat On Restless Legs
With generic Requips making headway in restless legs, investors had counted on cashing in on diabetic neuropathy.
FDA’s Refusal-To-File Slows Acorda’s Promising Niche MS Drug
Firm may need to refile NDA for mobility-boosting Fampridine-SR.